Amelioration of Type 2 Diabetes by Antibody-Mediated Activation of Fibroblast Growth Factor Receptor 1
Ai-Luen Wu, Ganesh A. Kolumam, Scott S. Stawicki et al. · Science Translational Medicine · 2011
Clinical use of recombinant fibroblast growth factor 21 (FGF21) for the treatment of type 2 diabetes and other disorders linked to obesity has been proposed; however, its clinical development has been challenging owing to its poor pharmacokinetics. Here, we describe an alternative antidiabetic strategy using agonistic anti-FGFR1 (FGF receptor 1) antibodies (R1MAbs) that mimic the metabolic effects of FGF21. A single injection of R1MAb into obese diabetic mice induced acute and sustained amelioration of hyperglycemia, along with marked improvement in hyperinsulinemia, hyperlipidemia, and hepatosteatosis. R1MAb activated the mitogen-activated protein kinase pathway in adipose tissues, but not in liver, and neither FGF21 nor R1MAb improved glucose clearance in lipoatrophic mice, which suggests that adipose tissues played a central role in the observed metabolic effects. In brown adipose tissues, both FGF21 and R1MAb induced phosphorylation of CREB (cyclic adenosine 5'-monophosphate response element-binding protein), and mRNA expression of PGC-1α (peroxisome proliferator-activated receptor-γ coactivator 1α) and the downstream genes associated with oxidative metabolism. Collectively, we propose FGFR1 in adipose tissues as a major functional receptor for FGF21, as an upstream regulator of PGC-1α, and as a compelling target for antibody-based therapy for type 2 diabetes and other obesity-associated disorders.
Cited by 176 works. doi:10.1126/scitranslmed.3002669
Authors
- Ai-Luen Wu
- Ganesh A. Kolumam
- Scott S. Stawicki
- Yongmei Chen
- Jun Li
- Jose Zavala‐Solorio
- Khanhky Phamluong
- Bo Feng
- Li Li
- Scot A. Marsters
- Lance Kates
- Nicholas van Bruggen
- Maya K. Leabman
- Anne Wong
- Howard Marvin Stern
- Elizabeth Luis
- Hok Seon Kim
- Daniel G. Yansura
- Andrew S. Peterson
References
- Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy
- FGF-21 as a novel metabolic regulator
- CREB regulates hepatic gluconeogenesis through the coactivator PGC-1
- Endocrine Regulation of the Fasting Response by PPARα-Mediated Induction of Fibroblast Growth Factor 21
- Hepatic Fibroblast Growth Factor 21 Is Regulated by PPARα and Is a Key Mediator of Hepatic Lipid Metabolism in Ketotic States
- Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity
- The Metabolic State of Diabetic Monkeys Is Regulated by Fibroblast Growth Factor-21
- Monoclonal antibodies: versatile platforms for cancer immunotherapy
- Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice
- Fibroblast Growth Factor 21 Corrects Obesity in Mice